Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: The M.D. Anderson Cancer Center Experience

Cancer Journal from Scientific American

Volumn 3, Issue 2, 1997, Pages 92-99

  Papadimitrakopoulou, Vali A ^a   Dimery, Isaiah W ^a   Lee, J Jack ^a   Perez, Cherie ^a   Hong, Waun K ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 FU; Cisplatin; induction chemotherapy; l leucovorin; locally advanced head and neck cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM STAGING; RADIATION INJURIES; STOMATITIS; SURVIVAL RATE;

EID: 0030951696     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Dimety IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
3. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
4. Vokes EE, Mick R, Lester EP et al. Cisplatin and fluorouracil does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol 1991;9:1376-1384.
5. Forastiere AA. Randomized trials of induction chemotherapy: a critical review. Hematol Oncol Clin North Am 1991;5:725-736.
6. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992;327:1115-1121.
7. Jacobs C. Head and neck cancer in 1994: a change in the standard of care (editorial). J Natl Cancer Inst 1994;86:250-251.
8. Vokes EE, Weichselbaum RR, Mick R et al. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992;84: 877-882.
9. Adelstein DJ, Saxton JP, Lavertu P et al. Concurrent radiation and chemotherapy (CT) versus (VS) radiotherapy (RT) alone in resectable stage III and IV squamous cell head and neck cancer (SCHNC): a phase III randomized trial [abstract 2015]. Proceedings of ASCO 1996;15:26.
10. Vokes EE, Kies M, Haraf DJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883.
11. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-847.
12. The Department of Veterans Affairs Laryngeal Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
13. Pfister DG, Strong E, Harrison L et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced resectable head and neck cancer. J Clin Oncol 1991;9:850-859.
14. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-899.
15. Urba SG, Forastiere AA, Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology 1989;3:79-88.
16. Trave F, Zakrzewski S, Petrelli N. Biochemical and pharmacologie basis for potentiation of 5-fluorouracil action by leucovorin. Monogr Natl Cancer Inst 1987;5:165-170.
17. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding of human thymidylate synthetase. Biochem Pharmacol 1980;30:247-257.
18. Vokes EE, Choi KE, Schilsky RL et al. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 1988;6:618-626.
19. Straw JA, Szapary D, Wynn WT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984;44:3114-3119.
20. Vokes EE, Schilsky RL, Weichselbaum RR et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacological analysis. J Clin Oncol 1990;8:241-247.
21. Rooney M, Kish J, Jacobs C et al. Improved complete response rate and survival in advanced head and neck cancer after three course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-1128.
22. Vokes EE, Ratain MJ, Mick R et al. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1993;2: 360-368.
23. Clark J, Busse P, Norris C Jr et al. Long term results of induction chemotherapy with cisplatin, 5-FU and high dose leucovorin (PFL) for squamous cell carcinoma of the head and neck (SC-CHN) [abstract]. Proceedings of ASCO 1996;15:317.
24. Pfister DG, Bajorin D, Motzer R et al. Cisplatin, fluorouracil, and leucovorin: increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:89-95.
25. Schneider M, Etienne MC, Milano G et al. Phase II trial of cisplatin, fluorouracil, and pure 1 folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995;7:1656-1662.
26. Beahrs OH, Henson DE, Hutter RVP: Manual for Staging Cancer (3rd ed). Philadelphia: Lippincott, 1988:27-50.
27. Dreyfuss AJ, Clark JR, Wright JE et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 1990;112: 167-172.
28. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:437-481.
29. Snedecor GW, Cochran WG: Statistical Methods (7th ed). Ames, IA: Iowa State University, 1980.
30. Peto R, Peto T. Asymptomatically efficient rank invariant test procedures. J R Stat Soc (A) 1990;135:409-414.
31. Milano G, Etienne MC, Renée A et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994;12:1291-1295.
32. Spaulding MB, Fischer SG, Wolf GT et al. Tumor response, toxicity and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592-1599.
33. Martin M, Gehanno P, Depondt J et al. A phase III study: induction carboplatin and 5 fluorouracil before locoregional treatment versus locoregional treatment alone in head and neck carcinomas [abstract]. Proceedings of ASCO 1994;13:281.
34. Karp DD, Vaughan CW, Carter R et al. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer: a long-term follow-up report. Am J Clin Oncol 1991;14:273-279.
35. Shirinian IH, Weber RS, Lippman SM et al. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Head Neck 1994;16:39-44.
36. Kraus DH, Pfister DG, Harrison LB et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. Otolaryngol Head Neck Surg 1994;111:31-37.
37. Horiot JC, LeFur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharynx carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
38. Forastiere AA. Use of paclitaxel (Taxol®) in squamous cell carcinoma of the head and neck Semin Oncol 1993;20[suppl 3]:56-60.
39. Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:553-537.
40. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabin (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 1994;5:543-547.